Fig. 2.

MYC expression is correlated with SUMOylation inhibition sensitivity in KRAS-mutant cancers. A Overview of the TaqMan Array analysis. HCT116 cells were treated with dimethyl sulfoxide (DMSO) or 1 µM TAK-981 for 48 h (n = 3). B, C Mini-volcano plot (B) and normalized heatmap (C) of differentially expressed genes (FC > I2I and FDR < 0.01, multiple t-tests) related to (A). FC, fold change; FDR, false discovery rate. D Correlation between MYC mRNA expression and the IC₅₀ of TAK-981 (n = 3 for each cell line). TAK-981-sensitive cells and resistant cells are represented by blue and red dots, respectively. The IC₅₀ of TAK-981-resistant cells are provisionally presented as 10 µM. r, correlation coefficient; R.², square of r (Pearson correlation coefficient). E MYC protein expression levels determined by immunoblotting representative TAK-981-sensitive cells (blue), TAK-981-resistant cells (red), and a normal epithelial cell line (black). F Immunoblotting of TAK-981-resistant cells transfected with GFP or MYC vectors. GFP, Green Fluorescent Protein; MYC-OE, MYC-overexpression. G Change of TAK-981 sensitivity in MYC-OE cells (See also Supplementary Figure S4)